We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
98 times I hit the requote icon before I got a deal.Just shows you what a sad existence I've got that I actually bothered to count.Good grief.
And don’t forget with the world increasing spending on health and LID offering a superior product that saves costs over competitors, politically do you think that spending will be pulled back right after cv19? That would be electoral suicide, na vfm and consolidation will be the order of the day and lid will be bought. All imo.
Trek
There are sales to RoW but less than main markets US, China and UK.
“The 19% growth in FY20 LiDCO product sales reflects growth in all regions compared with the prior year. LiDCO product sales grew by 28% in the USA to £1.8m (FY19: £1.4m), by 1% in the UK to £3.6m (FY19: £3.6m) and sales outside of the Company's direct markets were up 60% to £2.0m (FY19: £1.3m). The significant growth outside the UK included £0.4m growth in China from the launch of the new monitor and, as a result sales outside the UK now represent just over half (FY19: 43%) of LiDCO product sales.”
Re a raise, never say never but I have been through RNS’s back to April 14 and no placings. They are ebit positive have recurring revenues from monitors, directors have skin in this and looking at the last corporate presentation on the website they dedicate a couple of slides to M&A and how companies in the sector go for 4-7x revenues.
Don’t expect this to ten bag but it is a great growth story as a standalone business and should get a boost from cv19 particularly from US sales and a loosening of healthcare purse strings.
If you are looking for cv19 stocks I would recommend YGEN yet to move and SNG with a potential blockbuster treatment. I would not buy TILS, competitive space and coming from behind, TEK shell, funding always an issue and would just trade NCYT as a quicker test is about to be released From PHE. All imo...
Alternative there’s, Sutton Seeds, Baking trays, yeast, table tennis tables and jigsaw puzzles all pretty much sold out!
Trek
Question for Kiwi:
Why hasn't LIDco sold additional ICU units to the Italian healthcare system, or to France, or to Spain? If they had, surely they would have announced it already.
Are the same as this..they'll be doing a pi s s take placing.. like they all have.. it's a no from me Rampy Kiwi
Beyond that initial resistance and first target of 13.25p I have 17.5p followed by 27p, anyway not long to wait for the next RNS update here
Pre-Close Trading Update
LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following pre-close update in respect of its performance for the full year ended 31 January 2020 ("FY20").
LiDCO continues to make progress with developing a strong recurring revenue base through its Software as a Service ("SaaS") High Usage Programme ("HUP") business model and has achieved an excellent second half performance.
LiDCO product revenues for FY20 were up 19% to £7.4m (FY19: £6.2m), in line with management expectations. The growth in LiDCO product revenues more than outweighed the expected reduction in low margin third-party product sales. As a result, total revenues (including third party products) were up by 3% to £7.6m (FY19: £7.3m). The increased proportion of higher margin LiDCO revenues led to an increase in overall gross margin.
The Company now has a global contracted base of 286 HUP monitors (FY19: 164), generating total annualised contracted licence revenues of £2.2m (FY19: £1.4m) an increase of 57%.
The 19% growth in FY20 LiDCO product sales reflects growth in all regions compared with the prior year. LiDCO product sales grew by 28% in the USA to £1.8m (FY19: £1.4m), by 1% in the UK to £3.6m (FY19: £3.6m) and sales outside of the Company's direct markets were up 60% to £2.0m (FY19: £1.3m). The significant growth outside the UK included £0.4m growth in China from the launch of the new monitor and, as a result sales outside the UK now represent just over half (FY19: 43%) of LiDCO product sales.
In the second half of the year there was a net cash inflow of £0.2m, compared with a net cash outflow in H1 of £0.5m. The balance sheet remains strong with cash balances at 31 January 2020 of £1.4m (2019: £1.7m) and the Company remains debt free.
The Board expects to report positive adjusted EBITDA1 for FY20 (FY19: -£1.2m).
Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "After a strong first half in FY20, the team succeeded in delivering an even better second half performance. Our differentiated SaaS business model continues to drive our growth with the number of HUP monitors installed globally increasing nearly 75% and this has contributed to our expansion in recurring revenues. I am also pleased with our international sales growth as we now have the majority of our LiDCO product sales outside the UK, where we retain our market share and leadership position. This excellent performance leads to the expectation that we will report positive adjusted EBITDA for FY20."
BRIEF-Lidco Sells More Monitors To Hospitals In Wuhan Due To Covid-19
1 Min Read
March 9 (Reuters) - Lidco Group PLC:
* LIDCO GROUP PLC - INCREASED CHINA SALES DEMAND DUE TO COVID-19
* LIDCO- BEIJING GLORYWAY MEDICAL RECENTLY SOLD SMALL NUMBER OF MONITORS IN WUHAN, CHINA AS A DIRECT RESPONSE TO COVID-19 VIRUS OUTBREAK
* LIDCO - IN TALKS WITH HEALTHCARE INSTITUTIONS IN NUMBER OF AFFECTED AREAS, PREPARED TO BE FLEXIBLE TO MEET ANY SHORTTERM INCREASED MONITORING NEEDS Source text for Eikon:
Continued:
buywell reads this morning that in possibly 20% of cases heart damage , and those that suffer this and recover will obviously be impaired in some way,
This heart damage follows on after lung damage , read up on sepsis and septic shock.
My concern is that this seemingly mild disease , is for many going to either kill them or leave them permanently damaged to various degrees. The on-going cost to Health Services will IMO be considerable.
hTtps://www.cardiology-update.com/2020/03/12/covid-19-and-the-heart-2/
hTtps://www.tribuneindia.com/news/ludhiana/covid-19-infection-can-affect-heart-directly-experts-64871
This news is new re heart damage Google News 'heart damage Covid-19' and you will see a number of different stories/pieces in the last few days.
Worryingly it is not just the heart and lungs that are damaged , the liver and kidneys also are affected
'' From Washington state in the US, among 21 cases admitted to the ICU, 17 were admitted to ICU within 24 hours of hospital admission and 15 required intubation. Besides their respiratory distress, seven developed heart damage, four suffered kidney failure, and three liver damage. As of March 17, 11 of the patients had died, two had left the ICU, and eight still needed ventilation.''
hTtps://www.msn.com/en-au/news/techandscience/how-are-the-most-serious-covid-19-cases-treated-and-does-the-coronavirus-cause-lasting-damage/ar-BB11WxxJ
This damage to the body's organs : is called Sepsis a disease which now is responsible for over 20% of deaths worldwide , the worlds biggest single killer and most of you will never have heard of it.
Sepsis causes Septic Shock if not treated properly , lethal in 40% of cases
hTtps://www.dailyrecord.co.uk/news/scottish-news/sepsis-now-bigger-killer-cancer-21295621
''Most people recover from mild sepsis, but the average mortality rate for septic shock is about 40 percent.''
htTps://www.mayoclinic.org/diseases-conditions/sepsis/symptoms-causes/syc-20351214
Not a pretty picture is it
Yes flat out and working weekends
However buywell is asking them to go that extra mile and now also go on night shifts using additional staff to meet the orders which note must now be coming in 24 hrs a day
That is time zone differences --- staff working nights will answer incoming enquiries as they come in .
If you guys take the trouble to go back and read what buywell has said on this thread
Then you will see buywell has been 100% correct , the post that follows this will support what I have been posting about , namely that using a LiDCO Hemodynamic Monitor has been clinically proved to save a considerable percentage of patients lives that have Sepsis or Septic Shock.
Sepsis is a disease that causes the bodies own immune system to attack/destroy itself resulting in various organ damage , in the case of Covid-19
1) First the lungs
2) Second the Heart
3) Thirdly the Liver and Kidney
Truly a terrible disease BUT using LiDCO monitors has been proved to save lives and reduce bed time in hospital by 4 or 5 days , LOS Length of Stay.
Reducing length of stay by 5 days is CRITICAL in the number of patients that can be treated in a ICU .
Hospitals and countries around the world are in general trying to TRIPLE their ICU capabilities -- yes 300% increase -- to meet the ICU required capacity to treat the tide of Covid-19 patients.
Which buywell perceives, looking at Covid-19 in a purely economic light , as a requirement for the existing Hemodynamic Monitor market to leap by OVER 300% to meet the challenge.
Why over ?
Because many Hospitals and Health Services are either cash strapped and couldn't afford enough prior to Covid-19 , something LiDCO addressed by its High Usage Plan (HUP) initiative , however Covid-19 has now forced the hands of Governments and monies have been found.
dyor
What makes you think that? I need another 500K here so didums with whatever they do
I think you are wrong looks to me we hit the bottom on Friday!
That 15k trade at the end of the day is a buy not a sell, it’s mine a ‘small’ top up as I have a decent position here ahead of results and am adding as I can on dips. The spread is showing buys as sells and probably vice versa as the lse algorithm can’t always work it out correctly...
Date 03/04/20
Time 16:29
Stock Name LIDCO GROUP ORD GBP0.005
Action Buy
Order Type Market
Symbol LID
Quantity 15,000.00
Limit Price
Price £0.0733
Consideration £1,099.50
Commission £7.99
Stamp Duty £0.00
Levy £0.00
Total £1,107.49
Accrued Interest £0.00
Expiry Date n/a
Trek
That comment is at the end of the RNS... it opens with
“LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring company, announces that its Chinese distribution partner, Beijing Gloryway Medical Company, has recently sold a small number of monitors in Wuhan, China as a direct response to the COVID-19 virus outbreak.”
The whole RNS is a cautionary note, sure a small % need ICU but that seems to be becoming a bigger number as we peak. Like an earlier poster said you can bet orders for equipment will be arriving off the back of this and the NHS has had it’s debt written off! Health services will be ordering before this window closes and we get recurring revenues!
The dip today was on low volume, I had a buy order, it wasn’t filled so the price was only for an instant, it works both ways to the upside as well. This is aim. The main thing here is the prospects and the pipeline looks very good. The sp will reflect that especially at this time and it’s my opinion LID are for sale at 7x earnings. With health spending showing no sign of abating consolidation and M&A will happen. All imo.
Trek
the ICU need in their statement on 9th March
Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "The proportion of patients who are admitted to Intensive Care following COVID-19 infection remains low, however, there is significant clinical evidence that the use of advanced hemodynamic monitoring for patients in intensive care is clinically beneficial. Whilst the Board doesn't anticipate changing expectations at this time, the Company is prepared to support customers should they face an increased demand for intensive care."
I think it's a massive battle we are in now with this virus. Life and death stuff for many unfortunately.
I could be wrong about this and Lidco get loads of orders. I've been wrong many times before. There will be loads of money thrown at this current problem by the government. As the major of new york said last night...."i am not putting a dollar amount on human life". If we have the same attitude hopefully the government will provide plenty of all the best kit for all the sick patients.
GLA.
Hi Sausage, What is your profession?
Genuinely interested. You are alluding to the fact you are within the NHS.
I commend you, if so.
Sausage,
Before today you had never even heard of Lidco
Guys, lidco is a cardiac output monitoring device and needs an arterial line to function. It uses a theory called "pulse contour analysis" to assess beat beat changes in cardiac function and the response to fluid challenges from the arterial line trace.
You will only find arterial lines in patients who are in intensive care or having major surgery. These are not useful for other clinical areas such as GP practices.
As i said, It's a good bit of kit, it works, the company is helpful and there is no doubt a market for it. I just don't think that we will need 1000's of them like we do ventilators so I don't think it will boom big time. They will sell more than previously no doubt on the back of COVID i'm just not seeing massive orders.
Good luck all.
Sausage is talking rubbish. I have been trying to buy this stock but based in the US so proving difficult.
An old friend of mine who works at a London hospital told me that they have just bought 40 LIDCO monitors at £30k a pop! How many 100s of hospitals are there in England! If this is what they are selling to one then this company will be doing very well from COVID
Sausage, are you claiming to be a Doctor now?
Dimensions:
Dimensions
145mm x 90mm x 30mm
Yes. I've used the LIDCO monitor.
We prefer our first line cardiac output monitor as the oesophageal doppler version however it's from a competitor. We do have a LIDCO machine for patients who have coagulopathies where we will use the LIDCO. It is less invasive so has a lower incidence of bleeding complications in coagulopathic patients compared to an invasive oesophageal probe so there are instances where we'd go for this first.
With regards to monitors, all ITU patients are monitored as standard in Intensive care. The LIDCO is however an additional monitor. IMHO there's limited space for another one. It's a good bit of kit and has been around a while. I just don't think it's a hidden gem thats going to boom off the back of the current COVID situation. DYOR.
From the UK market leaders in hemodynamic monitoring, introducing Stimpod NMS 450X.
The Stimpod NMS450X Peripheral Nerve Stimulator is a quantitative Neuromuscular Blocking Agent monitor. The included tri-axial accelerometer allows the monitor to provide accurate and real-time feedback of train of four ratios and post-tetanic counts throughout the entire procedure. It can also be used for precision nerve location and close needle placements in regional anaesthesia procedures.
Quantitative NMT Monitoring
Train of Four | Post Tetanic Count | Double Burst | Tetanus | Twitch
Nerve Mapping & Locating
Simple
Simplifies LiDCOplus calibration process
OneTouch NMT Monitoring
Electrode Placement Verification
Quick Setup & No Calibration
Handheld
Data Connectivity
Economical
Reusable Sensor
Standard ECG Electrode Compatible
Quantitative NMT Monitoring reduces incidence of residual paralysis, increases operating room throughput and lowers cost
Proven
Compliant with AAGBI 2016 guidelines for TOF monitoring*
23 years of AMG research proves it identifies residual paralysis in 97% of patients
Pioneers of quantitative monitoring technology since 1998
Trusted by anaesthesiologists in over 40 countries
http://www.lidco.com/product/stimpod-nms-450x/